MedTrace Logo

Clinical Study of HRS-2129 for Acute Gouty Arthritis

NCT07706777 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-07-16

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Conditions

  • Acute Gouty Arthritis

Interventions

DRUG

HRS-2129 Tablet

HRS-2129 Tablet; high dose

DRUG

HRS-2129 Tablet

HRS-2129 Tablet; low dose

DRUG

Placebo

HRS-2129 Tablet Placebo

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2026-10-31
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706777 on ClinicalTrials.gov